Disease relevance of PGF2-beta

• Prostaglandin F2beta (PGF2beta), a stereoisomer of F2alpha was administered by ultrasonic nebulization to eight patients with bronchial asthma and four normal subjects in increasing doses up to 200 mug maximum dose [1].

High impact information on PGF2-beta

• Pretreatment with intragastric cysteamine, 30 mg/100 g, or intragastric prostaglandin F2 beta, 0.5 mg/100 g, significantly reduced the depth in the mucosa to which damage to capillaries extended [2].
• The purpose of this study was to measure the release of mucin glycoproteins from rat stomach after treatment with cysteamine and prostaglandin F2 beta, two structurally unrelated drugs that have been shown to protect the stomach against the noxious effects of alcohol and other damaging agents [3].
• Cysteamine and prostaglandin F2 beta stimulate rat gastric mucin release [3].
• Prostaglandin E2 (PGE2), PGF2 alpha, and PGF2 beta had little if any effect on LHRH or TRH release [4].
• The assay detected 9 alpha, 11 beta-prostaglandin F2 over the range of 20 pg to 1 ng, and the antiserum showed less than 0.04% cross-reaction with prostaglandin F2 alpha, prostaglandin F2 beta and 9 beta, 11 beta-prostaglandin F2 [5].

Biological context of PGF2-beta

• Pretreatment with various exogenous PGs that were biologically inactive (e.g. 6-keto-PGF1 alpha or PGF2 beta) or active (PGE2 and PGI2) but used in non-antisecretory doses prevented the formation of these gastric lesions ('cytoprotection') [6].

Anatomical context of PGF2-beta

• Secretion rate and electrolyte concentrations (Na+, K+ and Cl-) in the lacrimal fluid samples were determined before and after injections of small doses of prostaglandins (PGE1, PGE2, PGF1 alpha, PGF2 alpha, 15 epi-PGF2 alpha, PGF2 beta, PGA1 & PGA2) into the external maxillary artery [7].

References